Cefprozil

Revision as of 16:32, 27 September 2011 by Matt Pijoan (talk | contribs) (Protected "Cefprozil": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
Jump to navigation Jump to search

WikiDoc Resources for Cefprozil

Articles

Most recent articles on Cefprozil

Most cited articles on Cefprozil

Review articles on Cefprozil

Articles on Cefprozil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefprozil

Images of Cefprozil

Photos of Cefprozil

Podcasts & MP3s on Cefprozil

Videos on Cefprozil

Evidence Based Medicine

Cochrane Collaboration on Cefprozil

Bandolier on Cefprozil

TRIP on Cefprozil

Clinical Trials

Ongoing Trials on Cefprozil at Clinical Trials.gov

Trial results on Cefprozil

Clinical Trials on Cefprozil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefprozil

NICE Guidance on Cefprozil

NHS PRODIGY Guidance

FDA on Cefprozil

CDC on Cefprozil

Books

Books on Cefprozil

News

Cefprozil in the news

Be alerted to news on Cefprozil

News trends on Cefprozil

Commentary

Blogs on Cefprozil

Definitions

Definitions of Cefprozil

Patient Resources / Community

Patient resources on Cefprozil

Discussion groups on Cefprozil

Patient Handouts on Cefprozil

Directions to Hospitals Treating Cefprozil

Risk calculators and risk factors for Cefprozil

Healthcare Provider Resources

Symptoms of Cefprozil

Causes & Risk Factors for Cefprozil

Diagnostic studies for Cefprozil

Treatment of Cefprozil

Continuing Medical Education (CME)

CME Programs on Cefprozil

International

Cefprozil en Espanol

Cefprozil en Francais

Business

Cefprozil in the Marketplace

Patents on Cefprozil

Experimental / Informatics

List of terms related to Cefprozil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Synonyms: Cefprozilo [INN-Spanish], Cefprozil anhydrous, Cefprozilum [INN-Latin].

Brand Names: Arzimol, Brisoral, Cronocef, Procef, Serozil.

Dosing and Administration

Cefprozil tablets are administered orally.

Adults (13 years and older)

  • Pharyngitis/Tonsillitis: 500 mg every 24h for 10 days.
  • Acute sinusitis: 250 mg or 500 mg every 12h for 10 days.
  • Secondary bacterial infection of acute bronchitis and acute bacterial exacerbation of chronic bronchitis: 500 mg every 12h for 10 days.
  • Uncomplicated skin and skin structure infections: 250 mg every 12h for 10 days, 500 mg every 24h for 10 days, or 500 mg every 12h for 10 days.


Children (2 years-12 years)

  • Pharyngitis/Tonsillitis: 7.5 mg/kg every 12h for 10 days.
  • Uncomplicated skin and skin structure infections: 20 mg/kg every 24h for 10 days.


Infants & children (6 months-12 years)

  • Otitis media: 15 mg/kg every 12h 10 days.
  • Acute sinusitis: 7.5 mg/kg every 12h or 15 mg/kg every 12h for 10 days.


Renal impairment

  • For patients with a creatinine clearance of 0-29 mL/min, administer 50% of the standard dosage in mg.


Hepatic impairment

  • No dosage adjustment is necessary for patients with impaired hepatic function.


Adapted from the FDA Package Insert. Template:SIB